Experimental HIV Drugs
Experimental HIV Drugs
Apricitabine Gets a Second Chance
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 04 April 2011 23:53
- Written by Avexa
Avexa announced that has reached an agreement with the FDA to complete testing of its experimental NRTI apricitabine.
Gilead Quad Pill Works Better than Atripla
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 04 April 2011 23:46
- Written by Liz Highleyman
CROI 2011: Experimental Integrase Inhibitor Dolutegravir Looks Promising for People with Resistant HIV
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 15 March 2011 05:53
- Written by Liz Highleyman
The second-generation integrase inhibitor dolutegravir (formerly known as S/GSK1349572 or simply GSK572) demonstrated potent activity with a favorable tolerability profile for HIV patients with highly resistant virus in the second cohort of the VIKING study, researchers reported at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) this month in Boston. Results indicate that the drug works better when taken twice rather than once daily.
Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
- Details
- Category: HIV Treatment
- Published on Thursday, 31 March 2011 21:53
- Written by Vertex
The REALIZE study showed that adding telaprevir to standard hepatitis C therapy increased sustained response rates for people with previous unsuccessful treatment attempts, researchers reported this week at EASL 2011.
CROI 2011: New Tenofovir Pro-drug GS-7340 Looks Good in Early Study
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 10 March 2011 16:00
- Written by Paul Dalton
A new pro-drug formulation of tenofovir (currently marketed as Viread, also in the Truvada and Atripla combination pills) produces a higher drug concentration in lymphoid tissues that harbor HIV, offering the prospect of lower doses and new fixed-dose formulations, according to a presentation last week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. Further studies are needed to determine whether higher tenofovir concentrations will lead to worse bone or kidney toxicity. 
Web Design and Development by